Merck Shares Slip After Phase 3 Kidney Cancer Trial Fails to Meet Endpoints
Merck & Co. stock declined after the company and Eisai reported that their Phase 3 LITESPARK-012 study in advanced clear cell renal cell carcinoma did not reach its primary endpoints. The trial compared two experimental combination regimens to the established Keytruda plus Lenvima regimen and found no superior progression-free survival or overall s…